Global Biotechnology -Yearly Update 2006

Content

• 1. Industry Overview
  • 1.1 Industry growth
    • 1.1.2 Industry concentric
    • 1.1.3 Industry analysis
    • 1.1.4 R&D expenditure
    • 1.1.5 Number of players
    • 1.1.6 Financial flow
  • 1.2 References
• 2. Major Markets
  • 2.1 Economy
  • 2.2 Global market
  • 2.3 North America
    • 2.3.1 Biotechnology Industry
  • 2.4 Europe
    • 2.4.1 Biotechnology industry
  • 2.5 Asia- Pacific region
    • 2.5.1 Biotechnology Industry
  • 2.6 References
• 3. Major Players
  • 3.1 Introduction
  • 3.2 Novartis
  • 3.3 Amgen
  • 3.4 Genentech
  • 3.5 Genzyme
  • 3.6 Gilead Sciences
  • 3.7 Biogen Idec
  • 3.8 MedImmune Inc
  • 3.9 Invitrogen
  • 3.10 Merck Serono
  • 3.11 Millennium Pharmaceutical Inc
  • 3.12 References
• 4. Mergers and Acquisitions
  • 4.1 Introduction
  • 4.2 Major Disclosed Deals
  • 4.3 Undisclosed Deals
  • 4.4 Some Major Deals
  • 4.5 Trends in the deals
  • 4.6 References
• 5. Outlook
  • 5.1 References
• List Of Figures
  • Figure 1.1: Biotech Industry Revenues, 2002-2006
  • Figure 1.2: Global Revenue Break-up, 2006
  • Figure 1.3: Global Biotech Industry Net loss, 2002-2006
  • Figure 1.4: Global R&D Expenditure, 2002-2006
  • Figure 1.5: Companies in Biotech Industry, 2002-2006
  • Figure 1.6: Biotech Financing, 2002-2006
  • Figure 2.1: Global Real GDP Growth (2005-06)
  • Figure 2.2: Real GDP Growth Rate in the US (2005-06)
  • Figure 2.3: Real GDP Growth Rate in Canada (2005-06)
  • Figure 2.4: Real GDP Growth Rate in European Union (2005-06)
  • Figure 2.5: Real GDP Growth Rate in Japan (2005-06)
  • Figure 2.6: Real GDP Growth Rate in India (2005-06)
  • Figure 2.7: Real GDP Growth Rate in China (2005-06)
  • Figure 2.8: Major regions of Biotech Industry 2002- 2006
  • Figure 2.9: North American Biotech Revenue, 2002-2006
  • Figure 2.10: North American R&D Expenditure, 2002-2006
  • Figure 2.11: Biotech Companies in North America, 2002-2006
  • Figure 2.12: European Biotech Revenue, 2002-2006
  • Figure 2.13: Biotech Companies in Europe, 2002-2006
  • Figure 2.14: R&D Investment in Europe, 2002-2006
  • Figure 2.15: Biotech Revenue in Asia-Pacific, 2002-2006
  • Figure 2.16: Biotech Companies in Asia-Pacific, 2002-2006
  • Figure 2.17: R&D expenditure in Asia-Pacific, 2002-2006
• List Of Tables
  • Table 1.1: Major IPOs during 2006
  • Table 1.2: Major venture financings during 2006
  • Table 1.3: Selected partnering transactions during 2006
  • Table 1.4: Major drugs approved by FDA during 2006
  • Table 1.5: Major biotech drugs in pipeline (2006)
  • Table 1.6: Some important government R&D funding, 2006
  • Table 2.1: Major companies in North America
  • Table 2.3: Major European Companies 2006
  • Table 3.1: Top 10 Biotechnology Companies, 2006
  • Table 3.2: Novartis 2005- 2006
  • Table 3.3: Amgen 2005- 2006
  • Table 3.4: Genentech 2005-2006
  • Table 3.5: Genzyme 2005-2006
  • Table 3.6: Gilead Sciences 2005-2006
  • Table 3.7: Biogen Idec 2005 - 2006
  • Table 3.8: MedImmune 2005 - 2006
  • Table 3.9: Invitrogen 2005-2006
  • Table 3.10: Merck Serono 2005- 2006
  • Table 3.11: Millennium 2005 - 2006
  • Table 4.1: Major deals announced/completed 2006
  • Table 4.2: Undisclosed deals 2006